secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-05-14T20:11:39+00:00
Accession:  0001178913-26-002705
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion reports positive preclinical SIL204 data showing increased MHC-I in KRAS-mutated pancreatic cancer
--------------------------------------------------------------------------------

- SIL204 significantly increased MHC-I (HLA-ABC) surface expression in human KRAS G12R pancreatic cancer cells at 60 nM (p<0.05).
- Increased MHC-I may enhance T cell recognition, supporting potential combination with anti-PD-1 therapies like Keytruda.
- CEO Ilan Hadar said SIL204 may influence immune evasion pathways in addition to direct anti-tumor activity.
- Pancreatic cancer is immunologically resistant; MHC-I loss is a key immune evasion mechanism in KRAS-driven tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002705/0001178913-26-002705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002705/zk2635307.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-002705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer